Depomed To Present At Bank of America Merrill Lynch Healthcare Conference And UBS Global Healthcare Conference - 47 ABC - Delmarva's Choice

Depomed To Present At Bank of America Merrill Lynch Healthcare Conference And UBS Global Healthcare Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Depomed

NEWARK, Calif., May 9, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at two upcoming investor conferences:

Bank of America Merrill Lynch Healthcare Conference in Las Vegas Nevada on Thursday May 15 at 11:00 am Eastern Time (8:00 am Pacific Time).

UBS Global Healthcare Conference in New York City on Monday May 19 at 9:00 am Eastern Time (6:00 am Pacific Time).

The presentations will be webcast, and the webcasts can be accessed via the Investor Relations page of the Depomed website at www.depomed.com.  A recording of each webcast will be archived for 30 days on the company's website.

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.

CONTACT: August J. Moretti  
Depomed, Inc. 510.744.8000
amoretti@depomed.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
Powered by WorldNow All content © Copyright 2000 - 2014 WorldNow and WMDT. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.